Viruses Selected for the 2012-2013 Flu Vaccine
The Food and Drug Administration (FDA)'s Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Md. on Feb. 28, 2012, to select the influenza viruses for the composition of the influenza vaccine for the 2012-2013 U.S. influenza season.
During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2011-2012 vaccines, and the availability of candidate strains and reagents.
The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2012-2013 influenza season contain the following:
- an A/California/7/2009 (H1N1)-like virus
- an A/Victoria /361/2011 (H3N2)-like virus
- a B/Wisconsin /1/2010-like virus
The committee also recommended the following additional B strain for inclusion with the three strains included in the trivalent formulation for quadrivalent formulation influenza vaccines:
- a B/Brisbane/60/2008-like virus
A quadrivalent influenza vaccine will not be available for the 2012-2013 influenza season.
Â
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
